Preqin~3 min read
The form was never the reason fund managers stopped sharing.
Three weeks, one PM, one engineer, the head of engineering, and Legal and Sales on opposite sides.
- Role: Product strategy and design
- Timeline: 3 weeks
- Team: 1 PM, 1 engineer, head of engineering, me
- Impact: 5% → 15% retention
- Platform: Web
Account retention
up from 5%
Due diligence
down from 10 months
Both held through 2021, when I left Preqin. Retention comes from a two-week test with 20% of traffic diverted to the experiment and the rest left on the existing form, run alongside usability sessions on the same build. Due diligence comes from shadowing partners through a cycle, with deal closure for that same 20% read off an internal platform. Retention has a control group. Diligence is a before-and-after with none. Still missing: what retention counts (accounts, funds, or seats), and how many deals closed in that 20%.
Overview
Fund managers stopped contributing performance data, and the three easiest fixes aimed at a problem nobody had.
Preqin sells access to data that fund managers supply for free. When they stopped contributing, every subscriber got less for the same money. Six options were on the table. The three cheapest to build all made submission easier.
Worked with: 1 PM, 1 engineer, the head of engineering, Legal, and Sales; 6 partners interviewed.
What I owned
I owned
- Reframing the problem from collection to exchange, and the argument that took the three cheapest options off the table
- Research with partners at large and mid-market private equity funds
- Both experiments: the leaderboard that backfired and the quartile ranking that replaced it
- Keeping the form to what someone could complete in one sitting, despite a push for 32 fields
Decided with others
- Getting Legal and Sales to the same answer: I brokered it; they made the call
- The cohort floor beneath anonymization, with the head of engineering
Research
Partners were withholding numbers they were embarrassed by.
I interviewed 6 partners at large and mid-market private equity funds. The second question below changed the brief: what does a fund manager get for sharing a number that might embarrass them?
Decision: exchange, not collection
Winning that argument cost the cheapest roadmap.
If the cost of contributing is effort, tooling helps. If it is exposure, tooling speeds up submission for people who were never going to submit. Every research signal pointed at exposure.
The cheaper builds needed nobody to agree on what a contributor gets back. Moving to exchange meant asking for engineering time against a benefit I could only argue for.
Decision: the leaderboard
My first answer was a named leaderboard, and it backfired.
I considered a public leaderboard, a private benchmark, and no comparison. I was confident enough to ship a named ranking and did not plan mitigation, though the product was about to publish what partners guarded most closely. A partner said: “This doesn’t reflect who we are.” I removed it.
The research had already predicted this. I shipped it anyway.

Redesign
The version that worked kept the comparison and removed the identity.
Legal would not accept anything identifiable. Sales would not accept something partners could not compare with. I proposed an anonymized quartile position in an inline field, and both said yes. The timeline went from five sprints to two.
Anonymity holds only if the peer set is large enough to hide in. So the product requires four funds to share a benchmark and eight to share a median.


Scope
A short inline form shipped, and the 32 requested fields did not.
Every field had an internal advocate. I refused them because of the cumulative cost, and limited the form to what someone could finish in one sitting. The data model stayed thinner than the business wanted. We never tested the 32-field version, so this rests on reasoning.

Results
Retention rose from 5% to 15% and diligence cycles shortened from ten months to four.
I do not know what the leaderboard cost
The retention figure cannot separate recovery from damage. Did the later result overcome the harm, or cover it up? Getting the diagnosis right did not stop me getting the first remedy wrong.
